DrugBiological
NW-301V clinical trials
Also written NW-301V.
- studies test it
- 5
- open now
- 4
- in phase 3
- 0
- first study started
- 2024
Keep track of what changes. Save the NW-301V studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 4
TingBo Liang (1) · Neowise Biotechnology (1) · Peking University (1) · Ting Deng (1) · Tao Zhang (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses NW-301V is read from its arms, and is right about nine times in ten.
Testing it · 5
- Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V MutationNot yet recruitingPhase 1Neowise BiotechnologyNCT07875920Written as NW-301V
- T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid TumorRecruitingPhase 1Ting DengNCT06484790Written as NW-301V
- T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid TumorRecruitingPhase 1Tao ZhangNCT06484556Written as NW-301V
- NW-301 TCR-T in Patients With Advanced Solid TumorNot yet recruitingPhase 1Peking UniversityNCT06956261Written as NW-301V
- T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid TumorActive, not recruitingPhase 1TingBo LiangNCT06478251Written as NW-301V